Open AccessCombination antibiotics as a treatment for chronic Chlamydia ‐induced reactive arthritis: A double‐blind, placebo‐controlled, prospective trial
Author(s) -
Carter J. D.,
Espinoza L. R.,
Inman R. D.,
Sneed K. B.,
Ricca L. R.,
Vasey F. B.,
Valeriano J.,
Stanich J. A.,
Oszust C.,
Gerard H. C.,
Hudson A. P.
Publication year - 2010
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.27394
Subject(s) - azithromycin , placebo , medicine , doxycycline , chlamydia , chlamydia trachomatis , antibiotics , clinical endpoint , chlamydophila pneumoniae , reactive arthritis , antibacterial agent , randomized controlled trial , arthritis , gastroenterology , chlamydiaceae , immunology , microbiology and biotechnology , pathology , biology , alternative medicine
Abstract Objective Chlamydia trachomatis and Chlamydophila (Chlamydia) pneumoniae are known triggers of reactive arthritis (ReA) and exist in a persistent metabolically active infection state in the synovium, suggesting that they may be susceptible to antimicrobial agents. The goal of this study was to investigate whether a 6‐month course of combination antibiotics is an effective treatment for patients with chronic Chlamydia‐ induced ReA. Methods This study was a 9‐month, prospective, double‐blind, triple‐placebo trial assessing a 6‐month course of combination antibiotics as a treatment for Chlamydia ‐induced ReA. Eligible patients had to be positive for C trachomatis or C pneumoniae by polymerase chain reaction (PCR). Groups received 1) doxycycline and rifampin plus placebo instead of azithromycin; 2) azithromycin and rifampin plus placebo instead of doxycycline; or 3) placebos instead of azithromycin, doxycycline, and rifampin. The primary end point was the number of patients who improved by 20% or more in at least 4 of 6 variables without worsening in any 1 variable in both combination antibiotic groups combined and in the placebo group at month 6 compared with baseline. Results The primary end point was achieved in 17 of 27 patients (63%) receiving combination antibiotics and in 3 of 15 patients (20%) receiving placebo. Secondary efficacy end points showed similar results. Six of 27 patients (22%) randomized to combination antibiotics believed that their disease went into complete remission during the trial, whereas no patient in the placebo arm achieved remission. Significantly more patients in the active treatment group became negative for C trachomatis or C pneumoniae by PCR at month 6. Adverse events were mild, with no significant differences between the groups. Conclusion These data suggest that a 6‐month course of combination antibiotics is an effective treatment for chronic Chlamydia ‐induced ReA.